-
10058-F4: From Myc Dimerization to TERT Chromatin
2026-08-22
Explore how 10058-F4, a c-Myc-Max dimerization inhibitor, can connect transcription-factor disruption with TERT chromatin remodeling. This assay-focused guide translates recent stem-cell findings into practical decisions for oncology, apoptosis, and telomerase research.
-
RSL3: Glutathione Peroxidase 4 Inhibitor Guide
2026-08-22
RSL3 is a direct GPX4-targeting tool for modeling ferroptosis, redox failure, and oncogenic RAS vulnerability. This practical guide connects dose-finding, lipid-peroxidation readouts, rescue experiments, and the latest melanocyte findings to help researchers build more interpretable assays.
-
From Structured RNA to Translational Insight
2026-08-21
A mechanistic and strategic guide to selecting reverse transcription workflows for structured, scarce, and biologically informative RNA, using calcium-signaling adaptation as a model for why dependable RNA-to-cDNA conversion matters.
-
UbIA-MS Maps the Ubiquitin Interaction Landscape
2026-08-20
Zhang et al. introduced UbIA-MS, a quantitative affinity-enrichment mass spectrometry workflow that uses chemically synthesized diubiquitin to profile ubiquitin-linkage interactors directly from cell lysates. The study generated a broad interaction resource and identified linkage-selective biology, including K6 recognition by TAB2/TAB3 and K27 regulation by UCHL3, providing a framework for decoding ubiquitin signaling beyond individual candidate proteins.
-
Patient-Derived Gastric Cancer Assembloids
2026-08-20
Shapira-Netanelov and colleagues developed patient-derived gastric cancer assembloids that combine matched tumor organoids with tumor-derived stromal subpopulations, including fibroblasts, mesenchymal stem cells, and endothelial cells. The model reveals how stromal composition reshapes gene expression and drug sensitivity, creating a more physiologically relevant framework for studying resistance and personalized treatment strategies.
-
ATRX Loss Sensitizes High-Grade Glioma to RTK Inhibitors
2026-08-19
The reference study identifies ATRX deficiency as a potential determinant of high-grade glioma sensitivity to multi-targeted receptor tyrosine kinase and PDGFR inhibitors. Its findings also support evaluating RTK inhibitor–temozolomide combinations and incorporating ATRX status into the interpretation of glioma treatment studies.
-
Anti-M1R/B6R Antibodies for Orthopoxvirus Protection
2026-08-19
The reference study maps functional anti-M1R and anti-B6R monoclonal antibodies and shows that antibody cocktails and engineered bispecific formats can improve antiviral activity against orthopoxviruses. Its strongest translational contribution is the identification of a VH-CH1 switch region-inserting bispecific format that protected mice from vaccinia virus challenge.
-
Regorafenib Suppresses Melanoma Through RRM2
2026-08-18
The 2024 iScience study identifies RRM2 as a mechanistically important downstream effector of Regorafenib in melanoma and links this response to ERK/E2F3 signaling. Its combination of phenotypic assays, RNA sequencing, rescue experiments, and in vivo validation provides a framework for studying how a multikinase inhibitor can influence melanoma progression beyond angiogenic signaling.
-
Human SAN-Plexus Assembloids and Pacemaker Maturation
2026-08-18
This Cell Stem Cell study develops human pluripotent stem cell-derived assembloids that combine sinoatrial node, cardiac ganglionated plexus, and atrial-like organoids to model neural regulation of pacemaker maturation. By integrating electrophysiology, organoid assembly, and human SAN spatial transcriptomics, the authors identify a CGPO-derived prosaposin–GPR37 signaling program that promotes SAN-like maturation and provides a mechanistic framework for studying conduction dysfunction.
-
GPR30 in Spinal CCK+ Neurons and Neuropathic Pain
2026-08-17
The reference study identifies GPR30 in spinal cholecystokinin-positive neurons as a molecular and circuit-level contributor to nerve-injury-induced pain hypersensitivity. Its combination of cell-type targeting, synaptic analysis, and S1-to-spinal-cord circuit manipulation provides a framework for studying estrogen-sensitive pain mechanisms while highlighting important limits on therapeutic interpretation.
-
BCA Protein Assay Kit for Colitis Research
2026-08-17
Discover how the BCA Protein Assay Kit supports reproducible protein concentration measurement in DSS-induced colitis workflows, from tissue lysates to western blot normalization. This practical guide connects bicinchoninic acid protein quantification with the microbiota and metabolite findings reported for Limosilactobacillus reuteri FN041.
-
Annexin V Workflow for Apoptosis Research
2026-08-16
Use Annexin V, human recombinant, to convert phosphatidylserine externalization into a flexible readout for apoptosis assays, custom conjugates, and competition studies. This workflow connects early cell-death kinetics with practical controls, optimization steps, and in vivo assay design.
-
Clodronate Liposomes in Aging Macrophage Research
2026-08-15
Clodronate Liposomes provide a practical way to test whether macrophages causally drive age-related immune phenotypes. This article connects macrophage depletion with mitochondrial ROS, collagen, and actin-based phagocytosis mechanisms while emphasizing controls, route selection, and interpretation.
-
LSE mRNA Delivery for Durable T Cell Immunity
2026-08-14
Zhou and colleagues developed a lipid nanoparticle-stabilized emulsion that redirects mRNA toward antigen-presenting cells and coordinates delivery, expression, and antigen presentation in space and time. In mice, this design produced durable T cell responses, broader T cell repertoires, and activity in antiviral vaccine and tumor models, while also clarifying why carrier architecture can influence cellular immunity.
-
PMS Activates GPR30/PI3K/AKT in Osteoporosis
2026-08-14
The reference study integrates network pharmacology, zebrafish pharmacology, cellular osteoblast assays, and western blotting to investigate PMS, a low-concentration combination of psoralen, magnoflorine, and sweroside. Its findings support a model in which PMS promotes osteoblastic activity and mitigates dexamethasone-associated skeletal damage through GPR30-linked PI3K/Akt signaling, although further causal and translational studies are needed.